samedan logo
 
 
spacer
home > pmps > winter 2020 > counteracting the effects of an opioid overdose
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Counteracting the Effects of an Opioid Overdose





Respiratory depression can occur from accidental and/or intentional overdose of opioid type substances. The neurochemical process, by which the opioid substance binds with opioid receptors in the brain stem and then desensitises the level of carbon dioxide in the blood stream, fails to activate the breathing mechanisms, leading to respiratory failure and death (1). The overdose process can be interrupted and reversed with the administration of an opioid antagonist, such as naloxone, thereby blocking the effects of the ingested opioids.

In 1971, the FDA approved naloxone, the opioid antagonist, reversal medication for public use. This life-saving medication was initially labeled for intravenous, intramuscular, or subcutaneous use. For nearly 50 years, naloxone has been used by emergency medical personnel to counteract the effects of opioid overdoses (1). According to the Centers for Disease Control and Prevention, the administration of naloxone from the years 1996 to 2014 assisted in reversing the effects of opioid overdoses in an estimated 26,000 opioid users (2).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Dr Todd Pizitz is a licensed clinical and forensic psychologist in private practice in Vista, California. As a forensic psychologist, Todd works with those afflicted with various types of addiction. For the past 17 years, he has worked closely with private and public defense attorneys, family court services, the District Attorney’s Office, county adult and juvenile probation, drug court, and federal probation. Todd routinely conducts psychological evaluations on those involved in the legal system.

Donald R Mealing is a Business Entrepreneur with more than 25 years’ experience as a CEO over a variety of successful businesses. Don has served on numerous Boards, including 14 years on the Board of Regents, Harris Manchester College, Oxford University, UK. He was Founder and CEO of American Corrective Counseling Services, one of the largest private counselling diversion companies servicing courts and prosecutors across the US criminal justice system. Don has lost three close relatives to opioid overdose.
Print this page
Send to a friend
Privacy statement
News and Press Releases

European Commission Approves BYANNLI® (6-monthly Paliperidone Palmitate; PP6M) for the Maintenance Treatment of Schizophrenia in Adults

 BYANNLI® (6-monthly paliperidone palmitate; PP6M) is the first long-acting injectable schizophrenia treatment to be approved with a twice-yearly dosing regimen[1] . The approval is based on results from the Route 6 Study, which showed that 92.5 percent of patients treated with PP6M were relapse-free at the end of the 12-month double-blind phase1.  
More info >>

White Papers

Extractables and Leachables Testing: A Risk Based Approach

RSSL

Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement